Company News

Bristol, Tennessee-based Graceway Pharmaceuticals announced an agreement with Pfizer to acquire worldwide commercial rights for three investigational dermatological molecules. Two of the molecules will potentially treat oily skin and acne; both are in phase 2 of development. The third molecule, an ALK-5 inhibitor, is in pre-clinical development and would reduce surgical and traumatic scar formation. Financial terms of the deal were not disclosed.